ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GERN Geron Corp

3.30
-0.01 (-0.30%)
After Hours
Last Updated: 16:00:10
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,162,169
Bid Price 3.28
Ask Price 3.33
News -
Day High 3.34

Low
1.64

52 Week Range

High
3.735

Day Low 3.27
Company Name Stock Ticker Symbol Market Type
Geron Corp GERN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.30% 3.30 16:00:10
Open Price Low Price High Price Close Price Prev Close
3.32 3.27 3.34 3.29 3.31
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
17,391 6,162,169 $ 3.30 $ 20,322,803 - 1.64 - 3.735
Last Trade Time Type Quantity Stock Price Currency
16:03:02 priorref 3,001 $ 3.30 USD

Geron Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.81B 546.06M - 237k -184.13M -0.34 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Geron News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GERN Message Board. Create One! See More Posts on GERN Message Board See More Message Board Posts

Historical GERN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.483.503.183.3010,632,143-0.18-5.17%
1 Month2.023.501.642.7120,318,5421.2863.37%
3 Months2.033.501.642.4411,622,9411.2762.56%
6 Months2.163.501.642.278,363,1741.1452.78%
1 Year2.313.7351.642.487,058,2600.9942.86%
3 Years1.583.840.98992.255,154,4741.72108.86%
5 Years1.623.840.752.114,048,7961.68103.70%

Geron Description

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

Your Recent History

Delayed Upgrade Clock